PD-L1 expression on tumor cells (KEYNOTE-001 trial) [6], tumor mutation burden (TMB) [7], mismatch repair deficiency [8], and tumor-infiltrating lymphocytes (TIL) [9] are important biomarkers for predicting the response to anti-PD-1/PD-L1 antibodies. This evidence concerns the gene CD274 and hyperinsulinemic hypoglycemia, familial, 4.